This summer has been a busy time for Progenesis in hiring new personnel, setting up budgets with the awarding of the Phase II NIH SBIR grant and refining our R&D plans. Research and Development ProgressIn ramping up the R&D, especially with new personnel, it was necessary to revalidate the authenticity of the PGN strains develop …
Author Archives: progenesistech
2017 World Congress on Industrial Biotechnology
Progenesis (Dr. Hongwei Yu and myself) attended the 2017 World Congress on Industrial Biotechnology last week in Montreal. Our compliments to the organizers for putting together an informative and timely program. Thanks especially for the partnering sessions that set a record number for this year’s meeting. Also thanks to the people of Montreal who were …
Continue reading “2017 World Congress on Industrial Biotechnology”
Issue III, Summer 2017
In search for a topic to discuss for this Summer edition, I was dealing with recurrence of a problem that has afflicted me for the last six years, namely acid reflux. I am sure many of you share this problem, since it is estimated to affect 18-24% of the US population. In addition to the …
NIH SBIR Phase II Award
Progenesis is happy to announce that the company has been accepted into the NIH-funded Commercialization Accelerator Program (CAP). This program is managed by LARTA under a contract from the NIH. It provides a Primary Advisor for mentoring, honing a commercialization plan and introduction to a network of companies and entrepreneurs to help the company achieve …
Issue II, Spring 2017
Presently, the entire global supply of alginate is obtained from brown seaweeds. These are also known as macroalgae or kelp. The major species of commercial interest are Ascophyllum, Laminaria, Ecklonia, Durvillaea, Lessonia and Macrocystis, with Ascophyllum, Laminaria and Macrocystis being heavily used for alginate preparation. Have you wondered whether climate change, specifically global warming and …
Issue I, Winter 2017
Welcome to the first edition of our Progenesis blog discussing the latest developments, applications and concerns pertaining to alginate and its technology. As a disclaimer, Progenesis is a company that is using genetic engineering to commercialize the use of bacterial alginates and to produce custom alginates not found in seaweed, the current commercial source of …
Phase II SBIR Grant Application
The consulting firm BBCetc is helping progenesis submit a Phase II SBIR Grant Application. Once an applicant, such as Progenesis, has received a Phase I award, they are eligible to submit a Phase II grant application. The purpose of the Phase II award is to aid in the commercialization of the innovative technology. The amount …
Newsletter, Fall 2016
The company has been focusing on accomplishing the research objectives outlined in our funded NIH Phase I SBIR grant. For those of you not familiar with this grant program, it was instituted in 1977 through the National Science Foundation. Due to the success of this program, the Small Business Administration Lobbied Congress to extend it …
Progenesis Technologies, LLC. 